In this week's NEJM, Robert Coleman from the University of Sheffield in the UK and his colleagues report on a phase 3 study that was conducted to determine the effect of the adjuvant use of zoledronic acid in patients with breast cancer. Zoledronic acid is a bisphosphonate, and bisphosphonate has been shown to prevent or delay metastasis in in vivo models.
This Week in NEJM
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.